Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock.
San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio.
Cytori will acquire a pair of experimental cancer drugs, ATI-0918 and ATI-1123, which were designed to deliver chemotherapies more effectively and with fewer side effects than traditional formulations.
Get the full story at our sister site, Drug Delivery Business News.
The post Cytori buys Azaya’s nanoparticle tech in stock deal appeared first on MassDevice.
from MassDevice http://ift.tt/2jV0p5W
Cap comentari:
Publica un comentari a l'entrada